Loading...
Found 61 results for site-public-contact
A listing of site-public-contact medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of Tng462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with Mtap Loss and Ras Mutation
A
Anita Turk, MD
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel. Overall, the study comprises a dose escalation phase and a dose expansion phase.Interested in participating? For …
A Phase 1, First-In-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of Xmab541 in Advanced Solid Tumors
N
Nabil Adra, MD
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.Interested in participating? For more information about this research …
An Open-Label, Randomized Study of Bms-986489 (Atigotatug + Nivolumab Fixed-Dose Combination) Vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (Tigos-Ls)
M
Misty D. Shields, MD, PhD
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:Evaluate the efficacy of BMS-986489 vs durvalumabEvaluate the safety profile of BMS-986489Interested in participating? For more information about this research study or …
Circulating Tumor Dna in High-Risk Stage I and Clinical Stage II Germ-Cell Tumors
N
Nabil Adra, MD
Circulating tumor DNA (ctDNA) is a biomarker that shows how well the body responds to treatment for a disease. Blood and tissue specimens will be collected from patients to find out whether ctDNA can be detected in those specimens so that tools can be developed to predict the presence (or …
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
J
Jennifer King
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.Interested in …
Randomized Phase Iii Study of Mosunetuzumab Vs. Rituximab for Low Tumor Burden Follicular Lymphoma
K
Khushali Jhaveri
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of …
A Randomized Phase Ii Study of Venetoclax and Hma-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia (Aml): A Myelomatch Treatment Trial
R
Rita Assi
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation …
Shortstop-Her2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage Her2+ Breast Cancer Who Achieve Pcr After Neoadjuvant Chemotherapy with Her2 Blockade
K
Kathy Miller, MD
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal …
A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (Insight)
R
Rohan Maniar
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells …
Gain-Bcg: Gemcitabine Alternating With Intravesical Bcg Randomized Against Bcg Alone For Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer
H
Hristos Kaimakliotis, MD
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid …
Please choose between Voice or SMS based delivery of verification code
or